KR102093848B1 - Ral gtpases를 타겟으로 하는 항암용 화합물 및 이의 사용방법 - Google Patents

Ral gtpases를 타겟으로 하는 항암용 화합물 및 이의 사용방법 Download PDF

Info

Publication number
KR102093848B1
KR102093848B1 KR1020197005669A KR20197005669A KR102093848B1 KR 102093848 B1 KR102093848 B1 KR 102093848B1 KR 1020197005669 A KR1020197005669 A KR 1020197005669A KR 20197005669 A KR20197005669 A KR 20197005669A KR 102093848 B1 KR102093848 B1 KR 102093848B1
Authority
KR
South Korea
Prior art keywords
mmol
compound
phenyl
pyrazole
dihydropyrano
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020197005669A
Other languages
English (en)
Korean (ko)
Other versions
KR20190022929A (ko
Inventor
댄 테오도레스쿠
마이클 벰페
데이비드 로스
챠오 얀
필립 레이건
Original Assignee
더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 filed Critical 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트
Publication of KR20190022929A publication Critical patent/KR20190022929A/ko
Application granted granted Critical
Publication of KR102093848B1 publication Critical patent/KR102093848B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020197005669A 2014-07-10 2015-07-10 Ral gtpases를 타겟으로 하는 항암용 화합물 및 이의 사용방법 Expired - Fee Related KR102093848B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462022946P 2014-07-10 2014-07-10
US62/022,946 2014-07-10
PCT/US2015/040021 WO2016007905A1 (en) 2014-07-10 2015-07-10 Anti-cancer compounds target ral gtpases and methods of using the same

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020177002960A Division KR20170018084A (ko) 2014-07-10 2015-07-10 Ral gtpases를 타겟으로 하는 항암용 화합물 및 이의 사용방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207008228A Division KR20200034824A (ko) 2014-07-10 2015-07-10 Ral gtpases를 타겟으로 하는 항암용 화합물 및 이의 사용방법

Publications (2)

Publication Number Publication Date
KR20190022929A KR20190022929A (ko) 2019-03-06
KR102093848B1 true KR102093848B1 (ko) 2020-03-30

Family

ID=55064987

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020197005669A Expired - Fee Related KR102093848B1 (ko) 2014-07-10 2015-07-10 Ral gtpases를 타겟으로 하는 항암용 화합물 및 이의 사용방법
KR1020177002960A Ceased KR20170018084A (ko) 2014-07-10 2015-07-10 Ral gtpases를 타겟으로 하는 항암용 화합물 및 이의 사용방법
KR1020207008228A Ceased KR20200034824A (ko) 2014-07-10 2015-07-10 Ral gtpases를 타겟으로 하는 항암용 화합물 및 이의 사용방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020177002960A Ceased KR20170018084A (ko) 2014-07-10 2015-07-10 Ral gtpases를 타겟으로 하는 항암용 화합물 및 이의 사용방법
KR1020207008228A Ceased KR20200034824A (ko) 2014-07-10 2015-07-10 Ral gtpases를 타겟으로 하는 항암용 화합물 및 이의 사용방법

Country Status (9)

Country Link
US (4) US10202397B2 (enExample)
EP (2) EP3686202A1 (enExample)
JP (2) JP6672255B2 (enExample)
KR (3) KR102093848B1 (enExample)
CN (1) CN106604731B (enExample)
AU (2) AU2015287567A1 (enExample)
CA (1) CA2954560C (enExample)
IL (1) IL249959A0 (enExample)
WO (1) WO2016007905A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6672255B2 (ja) 2014-07-10 2020-03-25 ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレイト Ｒａｌ ＧＴＰアーゼを標的とする抗癌化合物及びそれを使用する方法
WO2016145252A1 (en) * 2015-03-10 2016-09-15 The Trustees Of Princeton University Shmt inhibitors
US10077273B2 (en) 2016-09-14 2018-09-18 The Trustees Of Princeton University SHMT inhibitors
CN109305972B (zh) * 2018-09-27 2021-07-09 广州医科大学 一种二氢吡喃并吡唑类化合物及其制备方法和应用
EP3766544A1 (en) * 2019-07-18 2021-01-20 Centre Hospitalier Regional Universitaire de Lille Novel pyrazolone derivatives as pd-1/pd-l1 interaction inhibitors
WO2022108730A1 (en) * 2020-11-18 2022-05-27 Texas Tech University System Therapies for cancer using small molecules that bind to and inhibit ral interacting proteins
CN114765064A (zh) * 2021-01-14 2022-07-19 南京天顶星医药科技有限公司 一种靶向RalA-GDP蛋白的药物的虚拟筛选方法
EP4337811A1 (en) 2021-05-10 2024-03-20 Novalum S.A. Cathode current collector bar of an aluminium production cell
CN114632147B (zh) * 2021-11-09 2024-04-30 南京大学 人类受试者心肌病的治疗

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120214824A1 (en) * 2010-12-08 2012-08-23 Bradley Tait Proteostasis regulators
WO2013096820A1 (en) * 2011-12-21 2013-06-27 The Regents Of The University Of Colorado Anti-cancer compounds targeting ral gtpases and methods of using the same

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4555396A (en) 1982-12-22 1985-11-26 Eastman Kodak Company Use of pyrylium and thiapyrylium compounds as biological stains
US5750550A (en) 1995-09-15 1998-05-12 Sanofi 2-(pyrazol-5-yl-oxymethyl)-1,2-benzisothiazol-3 (2H)-One 1, 1-dioxides and compositions and method of use thereof
JPH10279480A (ja) 1997-04-07 1998-10-20 Mitsubishi Chem Corp 皮膚組織障害の予防・治療剤
US6143471A (en) 1998-03-10 2000-11-07 Mitsubishi Paper Mills Limited Positive type photosensitive composition
WO2000040749A2 (en) 1999-01-06 2000-07-13 Genenews Inc. Method for the detection of gene transcripts in blood and uses thereof
US20070105105A1 (en) 2003-05-23 2007-05-10 Mount Sinai School Of Medicine Of New York University Surrogate cell gene expression signatures for evaluating the physical state of a subject
CA2533803A1 (en) 2003-07-29 2005-02-10 Bristol-Myers Squibb Company Biomarkers of cyclin-dependent kinase modulation
KR20080015123A (ko) 2005-05-25 2008-02-18 다나베 미츠비시 세이야꾸 가부시키가이샤 피라졸론 유도체를 포함하는 의약
WO2007016539A2 (en) 2005-07-29 2007-02-08 Children's Hospital Medical Center Gtpase inhibitors and methods of use and crystal structure of rac-1 gtpase
US20090221559A1 (en) 2005-09-02 2009-09-03 Jean-Francois Bonfanti Benzodiazepines as hcv inhibitors
WO2007056188A1 (en) 2005-11-04 2007-05-18 President And Fellows Of Harvard College Synthesis of inhibitors of ftsz
WO2007081966A2 (en) 2006-01-09 2007-07-19 University Of Southern California Small molecules for treating cancer and abnormal cell proliferation disorders
WO2008143894A2 (en) 2007-05-14 2008-11-27 Dana-Farber Cancer Institute, Inc. Phosphorylated rala
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2011010715A1 (ja) * 2009-07-24 2011-01-27 国立大学法人 東京大学 Ｐr－Ｓｅｔ７阻害剤
US20120252792A1 (en) * 2009-09-17 2012-10-04 The Regents Of The University Of Michigan Methods and compositions for modulating rho-mediated gene transcription
US8673913B2 (en) * 2009-11-13 2014-03-18 Case Western Reserve University SHP-2 phosphatase inhibitor
US9200046B2 (en) * 2011-06-29 2015-12-01 Cornell University Reporter system for high throughput screening of compounds and uses thereof
US20150011411A1 (en) 2011-12-21 2015-01-08 THE REGENTS OF THE UNIVERSITY OF COLORADO a body corporation Biomarkers of cancer
WO2013152313A1 (en) 2012-04-05 2013-10-10 The Regents Of The University Of California Compositions and methods for treating cancer and diseases and conditions responsive to growth factor inhibition
EP2858981A1 (en) 2012-06-06 2015-04-15 Basf Se Pyrazolopyrans having herbicidal and pharmaceutical properties
CN103910737B (zh) * 2014-03-25 2016-08-17 浙江师范大学 手性的1,4-二氢吡喃(2,3-c)吡唑衍生物及其合成方法和应用
JP6672255B2 (ja) 2014-07-10 2020-03-25 ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレイト Ｒａｌ ＧＴＰアーゼを標的とする抗癌化合物及びそれを使用する方法
WO2016205460A1 (en) * 2015-06-16 2016-12-22 Nantbioscience, Inc. Polycyclic derivatives targeting ral gtpases and their therapeutical applications

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120214824A1 (en) * 2010-12-08 2012-08-23 Bradley Tait Proteostasis regulators
WO2013096820A1 (en) * 2011-12-21 2013-06-27 The Regents Of The University Of Colorado Anti-cancer compounds targeting ral gtpases and methods of using the same

Also Published As

Publication number Publication date
CA2954560C (en) 2021-12-28
WO2016007905A1 (en) 2016-01-14
CA2954560A1 (en) 2016-01-14
EP3166609A4 (en) 2017-12-27
AU2020277293A1 (en) 2021-01-07
KR20200034824A (ko) 2020-03-31
AU2020277293B2 (en) 2021-10-21
JP2020105195A (ja) 2020-07-09
US20190135824A1 (en) 2019-05-09
KR20190022929A (ko) 2019-03-06
US10676480B2 (en) 2020-06-09
IL249959A0 (en) 2017-03-30
AU2015287567A1 (en) 2017-02-16
US10202397B2 (en) 2019-02-12
JP6672255B2 (ja) 2020-03-25
CN106604731A (zh) 2017-04-26
JP2017520588A (ja) 2017-07-27
US20200255442A1 (en) 2020-08-13
USRE48557E1 (en) 2021-05-18
EP3686202A1 (en) 2020-07-29
CN106604731B (zh) 2021-05-18
JP7102012B2 (ja) 2022-07-19
EP3166609B1 (en) 2020-03-11
US11472812B2 (en) 2022-10-18
EP3166609A1 (en) 2017-05-17
KR20170018084A (ko) 2017-02-15
US20170204112A1 (en) 2017-07-20

Similar Documents

Publication Publication Date Title
JP7102012B2 (ja) Ｒａｌ ＧＴＰアーゼを標的とする抗癌化合物及びそれを使用する方法
CN104271132B (zh) 靶向Ral GTP酶的抗癌化合物及使用其的方法
TWI304061B (en) Nitrogen-containing aromatic ring derivatives
US8999982B2 (en) Pharmaceutically active compounds as Axl inhibitors
US10640512B2 (en) Imidazopyrazinamine phenyl derivative and use thereof
TW201245152A (en) Novel compounds and compositions for the inhibition of NAMPT
KR20100134693A (ko) 2-아미노퀴나졸린 유도체
JP7189153B2 (ja) Ｐｌｋ１阻害剤としてのピロール誘導体
CN102485720A (zh) 热休克蛋白90抑制剂

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20250321

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-OTH-PC1903 (AS PROVIDED BY THE NATIONAL OFFICE); TERMINATION CATEGORY : DEFAULT_OF_REGISTRATION_FEE

Effective date: 20250321

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20250321